Therapeutic relevance of CD34+ cell dose in blood cell transplantation for cancer therapy

Journal of Clinical Oncology

Volumn 18, Issue 6, 2000, Pages 1360-1377

  Siena, Salvatore ^a   Schiavo, Roberta ^a   Pedrazzoli, Paolo ^a   Carlo Stella, Carmelo ^a  

^a UNIVERSITY OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOPOIETIC GROWTH FACTOR;

ADULT; AUTOTRANSPLANTATION; CANCER THERAPY; GRAFT FAILURE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC SYSTEM; HUMAN; PRIORITY JOURNAL; REVIEW; STEM CELL;

EID: 0034097402     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.6.1360     Document Type: Review

References (145)

1. Attal M, Harousseau JL, Stoppa AM, et al: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 335:91-97, 1996
2. Philip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1545, 1995
3. Gianni AM, Bregni M, Siena S, et al: High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 336:1290-1297, 1997
4. Gianni AM, Siena S, Bregni M, et al: High-dose sequential chemo-radiotherapy with peripheral blood progenitor cell support for relapsed or refractory Hodgkin's disease: A 6-year update. Ann Oncol 4:889-891, 1993
5. Horning SJ, Chao NJ, Negrin RS, et al: High-dose therapy and ' autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: Analysis of the Stanford University results and prognostic indices. Blood 89:801-813, 1997
6. Zittoun RA, Mandelli F, Willemze R, et al: Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 332:217-223, 1995
7. Antman KH: Critique of the high-dose chemotherapy studies in breast cancer: A positive look at the data. J Clin Oncol 17:30-34, 1999 (suppl)
8. Peters WP, Jones RB, Vredenburgh J, et al: A large, prospective, randomized trial of high-dose combination alkylating agents (CPB) with autologous cellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (AFM). Proc Am Soc Clin Oncol 15:121, 1996 (abstr 149)
9. Gianni AM, Siena S, Bregni M, et al: Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: Five year results. J Clin Oncol 15:2312-2321, 1997
10. Barquinero J, Kiem H-P, von Kalle C, et al: Myelosuppressive conditioning improves autologous engraftment of genetically marked hematopoietic repopulating cells in dogs. Blood 85:1195-1201, 1995
11. Schmitz N, Linch DC, Dreger P, et al: Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 347:353-357, 1995
12. Hartmann O, Le Corroller AG, Biaise D, et al: Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: Hematologic recovery and costs. Ann Int Med 126:600-607, 1997
13. Gratwohl A, Passweg J, Baldomero H, et al: Blood and marrow transplantation activity in Europe in 1996. Bone Marrow Transplant 22:227-240, 1998
14. Vose JM, Sharp JG, Chan W, et al: High-dose chemotherapy (HDC) and autotransplant for non-Hodgkin's lymphoma (NHL): Randomized trial of peripheral blood (PSCT) versus bone marrow (ABMT) and evaluation of minimal residual disease (MRD). Proc Am Soc Clin Oncol 16:90a, 1997 (abstr 315)
15. Azevedo WM, Aranha FJP, Gouvea JV, et al: Allogeneic transplantation with blood stem cells mobilized by rhG-CSF for hematological malignancies. Bone Marrow Transplant 16:647-653, 1995
16. Bensinger WI, Weaver CH, Appelbaum FR, et al: Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 85:1655-1658, 1995
17. Körbling M, Przepiorka D, Huh YO, et al: Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: Potential advantage of blood over marrow allografts. Blood 85:1659-1665, 1995
18. Schmitz N, Dreger P, Suttorp M, et al: Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 85:1666-1672, 1995
19. Metcalf D: The molecular control of cell division, differentiation commitment and maturation in haemopoietic cells. Nature 339:27-30, 1989
20. Morrison SJ, Shah NM, Anderson DJ: Regulatory mechanisms in stem cell biology. Cell 88:287-298, 1997
21. Dexter TM: Regulation of hemopoietic cell growth and development: Experimental and clinical studies. Leukemia 3:469-474, 1989
22. Gronthos S, Simmons PJ: The biology and application of human bone marrow stromal cell precursors. J Hematother 5:15-23, 1996
23. Trentin JJ: Influence of hematopoietic organ stroma (hematopoietic inductive microenvironments) on stem cell differentiation, in Gordon AS (ed): Regulation of Hematopoiesis (vol 1). New York, NY, Appleton, 1970, pp 161-185
24. Simmons PJ, Zannettino A, Gronthos S, et al: Potential adhesion mechanisms for localisation of haemopoietic progenitors to bone marrow stroma. Leuk Lymphoma 12:353-363, 1994
25. Gordon MY, Riley GP, Watt SM, et al: Compartmentalization of a haemopoietic growth factor (GM-CSF) by glycosaminoglycans in the bone marrow microenvironment. Nature 326:403-405, 1987
26. Prockop DJ: Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 276:71-74, 1997
27. Owen ME, Cave J, Joyner CJ: Clonal analysis in vitro of osteogenic differentiation of CFU-F. J Cell Sci 87:731-739, 1987
28. Owen ME, Friedenstein AJ: Stromal stem cells: Marrow-derived osteogenic precursors. CIBA Found Symp 136:42-60, 1988
29. Bennet JH, Joyner CJ, Triffitt JT, et al: Adipocyte cells cultured from marrow have osteogenic potential. J Cell Sci 99:131-139, 1991
30. Castro-Malaspina H, Gay RE, Resnick G, et al: Characterization of human bone marrow fibroblast colony-forming cells (CFU-F) and their progeny. Blood 56:289-301, 1980
31. Friedenstein AJ, Chailakhjan RK, Lalykina KS: The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet 3:393-403, 1970
32. Friedenstein AJ, Chailakhyan RK, Latsinik NV, et al: Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues: Cloning in vitro and retransplantation in vivo. Transplantation 17:331-340, 1974
33. Ashton BA, Allen TD, Howlett CR, et al: Formation of bone and cartilage by marrow stromal cells in diffusion chambers in vivo. Clin Orthop 151:294-307, 1980
34. Gronthos S, Graves SE, Ohta S, et al: The STRO-1 + fraction of adult human bone marrow contains the osteogenic precursors. Blood 84:4164-4173, 1994
35. Owen M: Lineage of osteogenic cells and their relationship to the stromal system. J Bone Miner Res 3:1-12, 1985
36. Almeida-Porada G, Ascensao JL, Zanjani ED: The role of sheep stroma in human haemopoiesis in the human/sheep chimaeras. Br J Haematol 93:795-802, 1996
37. Gan OI, Murdoch B, Larochelle A, et al: Differential maintenance of primitive human SCID-repopulating cells, clonogenic progenitors, and long-term culture-initiating cells after incubation on human bone marrow stromal cells. Blood 90:641-650, 1997
38. Li S, Champlin R, Fitchen JH, et al: Abnormalities of myeloid progenitor cells after "successful" bone marrow transplantation. J Clin Invest 75:234-241, 1984
39. O'Flaherty E, Sparrow R, Szer J: Bone marrow stromal function from patients after bone marrow transplantation. Bone Marrow Transplant 15:207-212, 1995
40. Domenech J, Gihana E, Dayan A, et al: Haemopoiesis of transplanted patients with autologous marrows assessed by long-term marrow culture. Br J Haematol 88:488-496, 1994
41. Carlo-Stella C, Tabilio A, Regazzi E, et al: Effect of chemotherapy for acute myelogenous leukemia on hematopoietic and fibroblast marrow progenitors. Bone Marrow Transplant 20:465-471, 1997
42. Eaves CJ: Peripheral blood stem cells reach new heights. Blood 82:1957-1959, 1993
43. Gordon MY: Physiological mechanisms in BMT and haemopoiesis: Revisited. Bone Marrow Transplant 11:193-197, 1993
44. Gordon MY, Blackett NM: Some factors determining the minimum number of cells required for successful clinical engraftment. Bone Marrow Transplant 15:659-662, 1995
45. Cavins JA, Scheer SC, Thomas ED, et al: The recovery of lethally irradiated dogs given infusions of autologous leukocytes preserved at -80°C. Blood 23:38-43, 1964
46. Storb R, Epstein RB, Ragde H, et al: Marrow engraftment by allogeneic leukocytes in lethally irradiated dogs. Blood 30:805-811, 1967
47. Fliedner TM: Blood stem cell transplantation: From preclinical to clinical models. Stem Cells 13:1-12, 1995
48. McCredie B, Freireich EJ, Hersh EM, et al: Early bone marrow recovery after chemotherapy following the transfusion of peripheral blood leukocytes in identical twins. Proc Am Assoc Cancer Res 11:54-60, 1970
49. Hershko C, Gale RP, Ho WG, et al: Cure of aplastic anaemia in paroxysmal nocturnal haemoglobinuria by marrow transfusion from identical twin: Failure of peripheral-leukocyte transfusion to correct marrow aplasia. Lancet 55:945-947, 1979
50. Abrams RA, Glaubiger D, Appelbaum FR, et al: Result of attempted hematopoietic reconstitution using isologous, peripheral blood mononuclear cells: A case report. Blood 56:516-520, 1980
51. Brito-Babapulle F, Bowcock SJ, Marcus RE, et al: Autografting for patients with chronic myeloid leukemia in chronic phase: Peripheral blood stem cells may have a finite capacity for maintaining haemopoiesis. Br J Haematol 73:76-81, 1989
52. Juttner CA, To LB, Haylock DN, et al: Circulating autologous stem cells collected in very early remission from acute non-lymphoblastic leukaemia produce prompt but incomplete haemopoietic reconstitution after high dose melphalan or supralethal chemoradiotherapy. Br J Haematol 61:739-745, 1985
53. To LB, Dyson PG, Juttner CA: Cell-dose effect in circulating stem-cell autografting. Lancet 2:404-405, 1986
54. Juttner CA, To LB, Ho JQK, et al: Early lympho-hemopoietic recovery after autografting using peripheral blood stem cells in acute non-lymphoblastic leukemia. Transplant Proc 20:40-43, 1988
55. Gianni AM, Bregni M, Siena S, et al: Rapid and complete hemopoietic reconstitution following combined transplantation of autologous blood and bone marrow cells: A changing role for high dose chemo-radiotherapy? Hematol Oncol 7:139-148, 1989
56. Sutherland DR, Anderson L, Keeney M, et al: The ISHAGE guidelines for CD34+ cell determination by flow cytometry. J Hematother 5:213-226, 1996
57. Siena S, Bregni M, Brando B, et al: Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: Enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor. Blood 74:1905-1914, 1989
58. Carlo-Stella C, Cazzola M, De Fabritiis P, et al: CD34-positive cells: Biology and clinical relevance. Haematologica 80:367-387, 1995
59. Krause DS, Fackler MJ, Civin CI, et al: CD34: Structure, biology, and clinical utility. Blood 87:1-13, 1996
60. Baumhueter S, Singer MS, Henzel W, et al: Binding of L-selectin to the vascular sialomucin CD34. Science 262:436-438, 1993
61. Civin CI, Gore SD: Antigenic analysis of hematopoiesis: A review. J Hematother 2:137-144, 1993
62. Scott MA, Gordon MY: In seach of the haemopoietic stem cell. Br J Haematol 90:738-743, 1995
63. + hematopoietic stem and progenitor cells, in Current Protocols in Cytometry. New York, NY, John Wiley & Sons, Inc, 1999, pp 6.4.1-6.4.22
64. Petzer AL, Hogge DE, Lansdorp PM, et al: Self-renewal of primitive human hematopoietic cells (long-term culture-initiating cells) in vitro and their expansion in defined medium. Proc Natl Acad Sci U S A 93:1470-1474, 1996
65. + hematopoietic cells. Blood 88:2619-2625, 1996
66. Siena S, Bregni M, Brando B, et al: Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood 77:400-409, 1991
67. Goodell MA, Rosenzweig M, Kim H, et al: Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nature Med 3:1337-1345, 1997
68. + cells. Exp Hematol 26:353-360, 1998
69. Bhatia M, Bonnet D, Murdoch B, et al: A newly discovered class of human hematopoietic cells with SCID-repopulating activity. Nature Med 4:1038-1045, 1998
70. Metcalf D: Hematopoietic regulators: Redundancy or subtlety? Blood 82:3515-3523, 1993
71. Eaves CJ, Cashman JD, Eaves AC: Methodology of long-term culture of human hemopoietic cells. J Tiss Cult Meth 13:55-62, 1991
72. Sutherland HJ, Eaves CJ, Eaves AJ, et al: Characterization and partial purification of human marrow cells capable of initiating long-term hematopoiesis in vitro. Blood 74:1563-1570, 1989
73. Parkman R: The future of placental-blood transplantation. N Engl J Med 339:1628-1629, 1998
74. Gratama JW, Orfao A, Barnett D, et al: Flow cytometric enumeration of CD34+ hematopoietic stem and progenitor cells: European Working Group on Clinical Cell Analysis. Cytometry 34: 128-142, 1998
75. Papadopoulos KP, Ayello J, Tugulea S, et al: Harvest quality and factors affecting collection and engraftment of CD34+ cells in patients with breast cancer scheduled for high-dose chemotherapy and peripheral blood progenitor cell support. J Hematother 6:61-68, 1997
76. Haas R, Möhle R, Frühauf S, et al: Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 83:3787-3794, 1994
77. Faucher C, Le Corroller AG, Chabannon C, et al: Autologous transplantation of blood stem cells mobilized with filgrastim alone in 93 patients with malignancies: The number of CD34+ cells reinfused is the only factor predicting both granulocyte and platelet recovery. J Hematother 5:663-670, 1996
78. + cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 19:303-310, 1997
79. Dercksen MW, Rodenhuis S, Dirkson MKA, et al: Subsets of CD34+ cells and rapid hematopoietic recovery after peripheral-blood stem-cell transplantation. J Clin Oncol 13:1922-1932, 1995
80. Klumpp TR, Goldberg SL, Magdalinski AJ, et al: Phase II study of high-dose cyclophosphamide, etoposide and carboplatin (CEC) followed by autologous hematopoietic stem cell rescue in women with metastatic or high-risk non-metastatic breast cancer: Multivariate analysis of factors affecting survival and engraftment. Bone Marrow Transplant 20:273-281, 1997
81. Ketterer N, Salles G, Raba M, et al: High CD34+ cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood 91:3148-3155, 1998
82. Watts MJ, Sullivan AM, Jamieson E, et al: Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: An analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma. J Clin Oncol 15:535-546, 1997
83. van der Wall E, Richel DJ, Holtkamp MJ, et al: Bone marrow reconstitution after high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation: Effect of graft size. Ann Oncol 5:795-802, 1994
84. Beguin Y, Baudoux E, Sautois B, et al: Hematopoietic recovery in cancer patients after transplantation of autologous peripheral blood CD34+ cells or unmanipulated peripheral blood stem and progenitor cells. Transfusion 38:199-208, 1998
85. Bensinger W, Appelbaum F, Rowley S, et al: Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 13:2547-2555, 1995
86. Glaspy JA, Shpall EJ, LeMaistre CF, et al: Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients. Blood 90:2939-2951, 1997
87. Siena S, Bregni M, Di Nicola M, et al: Durability of hematopoiesis following autografting with peripheral blood hematopoietic progenitors. Ann Oncol 5:935-941, 1994
88. Spencer V, Smith J, Kulkarni S, et al: Does transplantation of a high number of CD34+ cells predict more rapid engraftment following high-dose chemotherapy (hdc). Proc Am Soc Clin Oncol 11:131, 1992 (abstr 347)
89. Mortimer J, Hendricks D, Goodnough LT, et al: Pheresis of peripheral blood progenitor cells directed by CD34 counts. Proc Am Soc Clin Oncol 12:467, 1993 (abstr 1629)
90. Salazar R, Sola C, Maroto P, et al: Factors affecting CD34+ cell mobilization with cyclophosphamide + G-CSF and hematopoietic recovery after high-dose chemotherapy and stem cell support in solid tumour pts. Proc Am Soc Clin Oncol 17:95a, 1996 (abstr 368)
91. + cells in hematopoietic recovery and support measures required. Proc Am Soc Clin Oncol 15:538, 1996 (abstr 1746)
92. Glaspy J, Lu ZJ, Wheeler C, et al: Economic rationale for infusing optimal numbers of CD34+ cells in peripheral blood progenitor cell transplants (PBPCT). Blood 90:370a, 1997 (suppl 1) (abstr 1646)
93. Reisner Y, Martelli MF: Bone marrow transplantation across HLA barriers by increasing the number of transplanted cells. Immunol Today 16:437-440, 1995
94. Aversa F, Tabilio A, Velardi A, et al: Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 339:1186-93, 1998
95. Urbano-Ispizua A, Solano C, Brunet S, et al: Allogeneic transplantation of selected CD34+ cells from peripheral blood: Experience of 62 cases using immunoadsorption or immunomagnetic technique. Bone Marrow Transplant 22:519-525, 1998
96. Schmitz N, Bacigalupo A, Hasenclever D, et al: Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: First results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 21:995-1003, 1998
97. Ottinger HD, Beelen DW, Scheulen B, et al: Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. Blood 88:2775-2779, 1996
98. Bensinger WI, Clift R, Martin P, et al: Allogeneic peripheral blood stem cell transplantation in patients with advanced hematological malignancies: A retrospective comparison with marrow transplantation. Blood 88:2794-2800, 1996
99. Storek J, Gooley T, Siadak M, et al: Allogeneic peripheral blood stem cell transplantation may be associated with high-risk of chronic graft-versus-host disease. Blood 90:4705-4709, 1997
100. Brown RA, Adkins D, Khoury H, et al: Long-term follow-up of high-risk allogeneic peripheral blood stem cell transplant recipients: Graft-versus-host disease and transplant-related mortality. J Clin Oncol 17:806-812, 1999
101. Siena S, Bregni M, Bonsi L, et al: Clinical implications of the heterogeneity of hematopoietic progenitors elicited in peripheral blood by anticancer therapy with cyclophosphamide and cytokine(s). Stem Cells 11:72-75, 1993
102. Carlo-Stella C, Tabilio A: Stem cells and stem cell transplantation. Haematologica 81:573-587, 1996
103. To LB, Haylock DN, Simmons PJ, et al: The biology and clinical uses of blood stem cells. Blood 89:2233-2258, 1997
104. Millar BC, Millar JL, Shepherd V, et al: The importance of CD34+/CD33-cells in platelet engraftment after intensive therapy for cancer patients given peripheral blood stem cell rescue. Bone Marrow Transplant 22:469-475, 1998
105. Pecora AL, Preti RA, Gleim GW, et al: CD34+CD33-cells influence days to engraftment and transfusion requirements in autologous blood stem-cell recipients. J Clin Oncol 16:2093-2104, 1998
106. To LB, Haylock DN, Kimber RJ, et al: High levels of circulating haematopoietic stem cells in very early remission from acute non-lymphoblastic leukaemia and their collection and cryopreservation. Br J Haematol 58:399-410, 1984
107. To LB, Haylock DN, Thorpe D, et al: The optimisation of collection of peripheral blood stem cells for autotransplantation in acute myeloid leukaemia. Bone Marrow Transplant 4:41-47, 1989
108. To LB, Shepperd KM, Haylock DN, et al: Single high doses of cyclophosphamide enable the collection of high numbers of hematopoietic stem cells from peripheral blood. Exp Haematol 18:442-447, 1990
109. + cells. Blood 84:2930-2939, 1994
110. Copelan EA, Ceselski SK, Ezzone SA, et al: Mobilization of peripheral blood progenitor cells with high-dose etoposide and granulocyte colony-stimulating factor in patients with breast cancer, non-Hodgkin's lymphoma and Hodgkin's disease. J Clin Oncol 15:759-765, 1997
111. Schwartzberg LS, Birch R, Hazelton B, et al: Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony-stimulating factor. J Hematother1:317-327, 1992
112. Omode P, Tarella C, Palumbo A, et al: Multiple myeloma: Reduced plasma cell contamination in peripheral blood progenitor cell collections performed after repeated high-dose chemotherapy courses. Br J Haematol 99:685-691, 1997
113. Dührsen U, Sheridan WP: G-CSF: Role in bone marrow and peripheral blood stem cell transplantation, in Mertelsmann R, Herrmann F (eds): Haematopoietic Growth Factors in Clinical Applications. New York, NY, Marcel Dekker, 1995, pp 241-252
114. Efremidis AP, Koumakis G, Filis J, et al: Peripheral blood progenitor cell (PBPC) transplantation with a single apheresis in patients with lymphoma, myeloma and solid tumours. Eur J Haematol 57:269-277, 1996
115. Mahe B, Milpied N, Hermouet S, et al: G-CSF alone mobilizes sufficient peripheral blood CD34+ cells for positive selection in newly diagnosed patients with myeloma. Br J Haematol 92:263-268, 1996
116. Alegre A, Toma JF, Martinez-Chamorro C, et al: Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: High-dose cyclophosphamide plus GM-CSF vs G-CSF alone. Bone Marrow Transplant 20:211-217, 1997
117. Nademanee A, Sniecinski I, Schmidt GM, et al: High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells. J Clin Oncol 12:2176-2186, 1994
118. Sheridan WP, Begley CG, Juttner CA, et al: Effect of peripheral blood progenitor cells mobilised by G-CSF (filgrastim) on platelet recovery after high-dose chemotherapy. Lancet 339:640-644, 1992
119. Zeller W, Gutensohn K, Stockschlader M, et al: Increase of mobilized CD34-positive peripheral blood progenitor cells in patients with Hodgkin's disease, non-Hodgkin's lymphoma, and cancer of the testis. Bone Marrow Transplant 17:709-713, 1996
120. Haas R, Ho AD, Bredthauer U, et al: Successful autologous transplantation of blood stem cells mobilized with recombinant human granulocyte-macrophage colony-stimulating factor. Exp Hematol 18: 94-98, 1990
121. Peters WP, Rosner G, Ross M, et al: Comparative effects of granulocyte-colony stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood 81:1709-1719, 1993
122. Bishop MR, Anderson JR, Jackson JD, et al: High-dose therapy and peripheral blood progenitor cell transplantation: Effects of recombinant human granulocyte-macrophage colony-stimulating factor on the autograft. Blood 83:610-616, 1994
123. Tabbara IA, Ghazal CD, Ghazal HH: The role of granulocyte colony-stimulating factor in haematopoietic stem cell transplantation. Cancer Invest 15:353-357, 1997
124. Weaver CH, Schwartzenberg LS, Birch R, et al: Collection of peripheral blood progenitor cells after the adminstration of cyclophosphamide, etoposide and granulocyte-colony-stimulating factor: An analysis of 497 patients. Transfusion 37:896-903, 1997
125. Neben S, Marcus K, Mauch P: Mobilization of hemopoietic stem and progenitor cell subpopulations from the marrow to the blood of mice following cyclophosphamide and/or granulocyte colony-stimulating factor. Blood 81:1960-1961, 1993
126. Knudsen LM, Gaarsdal E, Jensen L, et al: Improved priming of mobilization of and optimal timing for harvest of peripheral blood stem cells. J Hematother 5:399-406, 1996
127. 2) and granulocyte colony-stimulating factor in patients with multiple myeloma. Bone Marrow Transplant 17:691-697, 1996
128. Demirer T, Buckner CD, Storer B, et al: Effect of different chemotherapy regimens on peripheral-blood stem-cell collections in patients with breast cancer receiving granulocyte colony-stimulating factor. J Clin Oncol 15:684-690, 1997
129. Nemunaitis J, Rosenfeld C, Bolwell B, et al: Phase II randomized trial comparing SDZ ILE 965 (rhIL-3) to sequential and combination administration of rhIL-3 and leukin or neupogen in the mobilization of peripheral blood progenitor cells for autologous transplant (PBSCT) in patients with lymphoid malignancy or breast cancer. Blood 82:365a, 1993 (suppl 1) (abstr 1446)
130. Donato M, Korbling J, Gajewski J, et al: Peripheral blood stem cell (PBSC) mobilisation with chemotherapy and G-CSF versus G-CSF with or without IL-3. Proc Am Soc Clin Oncol 16:91a, 1997 (abstr 332)
131. Winter JN, Lazarus HM, Rademaker A, et al: Phase I/II study of combined granulocyte colony-stimulating factor and granulocytemacrophage colony-stimulating factor administration for the mobilization of hematopoietic progenitor cells. J Clin Oncol 14:277-286, 1996
132. Winter JN, Mangan C, Byrd K, et al: Combine rG-and GM-CSF priming of peripheral blood stem cell harvests. Blood 82:293a, 1993 (suppl 1) (abstr 1157)
133. Lane TA, Law P, Mráruyama M, et al: Harvesting and enrichment of hematopoietic progenitor cells mobilized into periperal blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: Potential role in allogeneic marrow transplantation. Blood 85:275-282, 1995
134. Molineux G, McCrea C, Van XQ, et al: Flt-3 ligand synergizes with granulocyte colony-stimulating factor to increase neutrophil numbers and to mobilize peripheral blood stem cells with long-term repopulating potential. Blood 89:3998-4004, 1997
135. Brasel K, McKenna HJ, Charrier K, et al: Synergistic effects in vivo of FLT3 ligand with GM-CSF or G-CSF in mobilization of colony forming cells in mice. Blood 86:499a, 1995 (abstr 1986)
136. Lebsack ME, McKenna HJ, Hoek JA, et al: Safety of FLT3 ligand in healthy volunteers. Blood 90:170a, 1997 (suppl) (abstr 1751)
137. Bishop MR, Jackson JD, O'Kane-Murphy B, et al: Phase I trial of recombinant fusion protein PIXY321 for mobilization of peripheralblood cells. J Clin Oncol 14:2521-2526, 1996
138. Stiff P, Gingrich R, Luger S, et al: Improved PBPC collection using STEMGEN® (stem cell factor, SCF) and filgrastim (G-CSF) compared to G-CSF alone in heavily pretreated lymphoma (NHL) and Hodgkin's disease (HD) patients. Blood 90:591a, 1997 (abstr 2628)
139. Harrouseau JL, Facon T, Maloisel F, et al: Stem cell factor in combination with filgrastim following chemotherapy improves peripheral blood progenitor cell mobilisation. Br J Haematol 102: 1998 (suppl 1) (abstr O-0600)
140. Weaver A, Chang J, Wrigley E, et al: Randomized comparison of progenitor-cell mobilization using chemotherapy, stem cell factor, and filgrastim or chemotherapy plus filgrastim alone in patients with ovarian cancer. J Clin Oncol 16:2601-2612, 1998
141. Shpall EJ, Wheeler CA, Turner SA, et al: A randomized phase 3 study of PBPC mobilization by stem cell factor (SCF, STEMGEN®) and filgrastim in patients with high-risk breast cancer. Blood 90:591a, 1997 (abstr 2627)
142. Weaver A, Ryder D, Crowther D, et al: Increased numbers of long-term culture-initiating cells in the apheresis product of patients randomized to receive increasing doses of stem cell factor administered in combination with chemotherapy and a standard dose of granulocyte colony-stimulating factor. Blood 88:3323-3328, 1996
143. Weaver A, Testa NG: Stem cell factor leads to reduced blood processing during apheresis or the use of whole blood aliquots to support dose-intensive chemotherapy. Bone Marrow Transplant 22:33-38, 1998
144. Gianni AM: Where do we stand with respect to the use of peripheral blood progenitor cells? Ann Oncol 5:781-784, 1994
145. Wynn RP, Cross MA, Hatton C, et al: Accelerated telomere shortening in young recipients of allogeneic bone-marrow transplants. Lancet 351:178-181, 1998